Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
- View all journals
Thyroid cancer articles from across Nature Portfolio
Thyroid cancers are tumours of the thyroid gland, and originate from follicular or parafollicular cells. These are often caused by radiation exposure, and can present as a nodule in the anterior region of the neck.
Latest Research and Reviews
Pan-cancer analysis of the immunological and oncogenic roles of ATAD2 with verification in papillary thyroid carcinoma
- Zhecheng Li
Germline variant affecting p53β isoforms predisposes to familial cancer
Pathogenic germline variants in TP53 predispose to a variety of cancers, but variants solely affecting alternatively spliced isoforms of TP53 are understudied. Here, the authors identify a heterozygous stop-lost variant that specifically affects p53β isoforms and predisposes to familial cancer using germline whole-exome sequencing and functional genomics assays.
- Stephanie A. Schubert
- Tom van Wezel
Thyroid nodules: diagnosis and management
Thyroid nodules are common; the majority are benign and asymptomatic, and therefore the main aim of the diagnostic process is to determine their clinical significance without leading to overdiagnosis and, consequently, overtreatment, as outlined in this article.
- Giorgio Grani
- Marialuisa Sponziello
- Cosimo Durante
Patterns and indications of intraoperative nerve monitoring usage during thyroidectomy and parathyroidectomy in Spain: results of a national survey of endocrine surgeons
- Manuel Durán Poveda
- Juan Manuel Martos Martínez
- Gil Rodríguez-Caravaca
Improved survival after primary tumor resection in distant metastasis medullary thyroid carcinoma: a population-based cohort study with propensity score matching
- Xianzhao Deng
The neurotransmitter calcitonin gene-related peptide shapes an immunosuppressive microenvironment in medullary thyroid cancer
Medullary thyroid cancer (MTC) is a neuroendocrine tumor that originates from thyroid parafollicular cells, generally associated with a poor prognosis. By comparing MTC with less aggressive papillary thyroid cancer, here the authors find that the neurotransmitter calcitonin gene-related peptide (CGRP) promotes an immunosuppressive microenvironment in MTC.
- Yingtong Hou
- Haipeng Xiao
News and Comment
Activity of selpercatinib confirmed in phase iii trials.
- Diana Romero
Engineering stem cells to recapitulate thyroid cancer
- Shimona Starling
Activity of selpercatinib in RET fusion-positive cancers confirmed
Post-operative radioactive iodine administration in patients with low-risk thyroid cancer.
Radioactive iodine (RAI) treatment is used in patients with thyroid cancer to treat disease and to eradicate normal thyroid remnants. Routine post-operative administration of RAI is no longer indicated in patients with low risk thyroid cancer and might instead be used selectively in patients with a post-operative high serum level of thyroglobulin.
- Sophie Leboulleux
- Isabelle Borget
- Martin Schlumberger
Radioiodine can be omitted in low-risk disease
Understanding the ever-changing incidence of thyroid cancer
This Comment article provides a behind-the-scenes perspective and update of our 2016 Review, which discussed possible factors contributing to thyroid cancer incidence trends worldwide. We also highlight promising research directions that are improving the understanding of thyroid cancer aetiology.
- Cari M. Kitahara
- Julie A. Sosa
Quick links
- Explore articles by subject
- Guide to authors
- Editorial policies
Thyroid Cancer Research Results and Study Updates
See Advances in Thyroid Cancer Research for an overview of recent findings and progress, plus ongoing projects supported by NCI.
For people with lung cancer and medullary thyroid cancer whose tumors have changes in the RET gene, selpercatinib improved progression-free survival compared with other common treatments, according to new clinical trial results.
Women are far more likely than men to be diagnosed with small thyroid cancers that probably would have never caused problems during their lifetime, a new study finds. The results may help explain why thyroid cancer seems to be more common in women.
FDA has granted accelerated approval for selpercatinib (Retevmo) to treat certain patients with thyroid cancer or non-small cell lung cancer whose tumors have RET gene alterations. The drug, which works by blocking the activity of RET proteins, was approved based on the results of the LIBRETTO-001 trial.
The test measures genomic changes in thyroid biopsy samples and generates a score based on how strongly each change is associated with thyroid cancer. A study showed the test accurately identified samples that, after surgery, were found to be benign.
FDA recently approved the targeted-drug combination to treat patients with advanced melanoma and a subset of patients with a rare and aggressive form of thyroid cancer whose tumors have a specific mutation in the BRAF gene.
Patients who choose not to pursue immediate biopsy or treatment for small, asymptomatic thyroid cancers, or suspected cancers, can experience a lack of support from doctors and loved ones, a new study shows.
After rising steadily since the 1990s, the incidence of thyroid cancer in the United States may be leveling off, according to an analysis of data from NCI’s SEER program.
The FDA has approved lenvatinib (Lenvima) to treat some patients with the most common type of thyroid cancer.
IMAGES
VIDEO